Keith Ward
InterveXion Therapeutics of Little Rock, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, announced Monday the appointment of Keith Ward, Ph.D., to president and CEO.
Ward most recently served as executive vice president and chief development officer for Reata Pharmaceuticals. Prior to joining Reata, he developed ophthalmic products as global vice president of pharmaceutical research and development for Bausch & Lomb Inc.
Ward has more than 20 years of experience in the pharmaceutical industry, including C-suite leadership in both public and private companies. He began his career with SmithKline Beecham Pharmaceuticals and GlaxoSmithKline PLC.
Ward earned a bachelor’s degree in toxicology with a minor in chemistry from Northeast Louisiana University and a Ph.D. in toxicology from the University of North Carolina at Chapel Hill.
Sign up for Daily E-news
